Expert Perspectives & Insights into CAR T-cell Therapy in Relapsed / Refractory Acute Lymphoblastic Leukemia   - Episode 17

Logistical and Access Challenges with CAR T-cell Therapy in R/R ALL

, , , ,

Experts in acute lymphoblastic leukemia examine the logistical challenges associated with CAR T-cell therapy delivery and assess the frequency of patient attrition due to manufacturing delays.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of CAR T-cell Therapies in R/R B-cell ALL
    EP. 2: CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel
    EP. 3: Considerations for Dosing and Lymphodepletion with CAR T-cell Therapy in R/R ALL
    EP. 4: Expert Perspectives on CAR T-Cell Therapy Logistics: Collection to Treatment
    EP. 5: Overview of Available Treatment Options in R/R B-cell ALL
    EP. 6: Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives
    EP. 7: Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data
    EP. 8: Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
    EP. 9: Expert Perspectives on Bridging Therapy Strategies Prior to CAR T-cell Therapy
    EP. 10: Sequencing Strategies with CAR T-cell Therapy in Patients with or without Prior Blinatumomab Treatment
    EP. 11: Translating Data Updates from FELIX and ZUMA-3 to the Clinical Practice Setting
    EP. 12: Expert Perspectives on the Potential Impact of Obe-cel on the Treatment Landscape for R/R ALL
    EP. 13: Treatment Approaches with Consolidation and Maintenance Post CAR T-cell Therapy
    EP. 14: Future Perspectives on CAR T-cell Therapy in R/R B-cell ALL
    EP. 15: Frequency, Correlation with Clinical Outcomes, and Risk Factors for Severe CRS and ICANS in CAR T-cell Therapy
    EP. 16: Expert Perspectives in Monitoring and Management Strategies for CRS, ICANS, and Other Long-Term Toxicities Associated with CAR T-cell Therapy
    Now Viewing
    EP. 17: Logistical and Access Challenges with CAR T-cell Therapy in R/R ALL
    EP. 18: Strategies and Resources for Overcoming Barriers to CAR T-Cell Therapy
    EP. 19: Role of Multidisciplinary Team & Logistics of CAR T-cell Therapy Administration in the Inpatient or Outpatient Setting
    EP. 20: Key Takeaways and Clinical Pearls in the Treatment of R/R ALL

    Video content above is prompted by the following:

    • What are some logistical barriers with delivery of CAR T-cell Therapy?
    • How frequently do your patients have to drop out from CAR T-cell therapy due to manufacturing time? How does it compare to the rates in the ZUMA-3 and FELIX Study?
    • How feasible is it for your patients to remain in close proximity to the hospital per the REMS requirements?
    • Have you observed any additional or unique access challenges in minority populations?
    x